Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis.
Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab.
Multiple Sclerosis in Gulf War Era Veterans. 2. Military Deployment and Risk of Multiple Sclerosis in the First Gulf War.
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
The Puerto Rico study for the prevalence of Multiple Sclerosis.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Alcohol as a Modifiable Lifestyle Factor Affecting Multiple Sclerosis Risk.
Mitochondrial changes within axons in multiple sclerosis: an update.
Shape Analysis of the Corpus Callosum and Cerebellum in Female MS Patients with Different Clinical Phenotypes.
Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996-2008.
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.
Balance and Gait in People with Multiple Sclerosis: A Comparison with Healthy Controls and the Immediate Change after an Intervention based on the Bobath Concept.
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis.
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.
Animal assisted interventions in neurorehabilitation: A review of the most recent literature.
MRI mean diffusivity detects widespread brain degeneration in multiple sclerosis.
Scoring treatment response in patients with relapsing multiple sclerosis.
Cognitive dysfunction in multiple sclerosis.
Multiple sclerosis and pain.
Future MS care: a consensus statement of the MS in the 21st Century Steering Group.
Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?

Pages